GlassScriptPhysician profile
Rekha Pandula
NPI 1134183585
$2,852.92
in general payments reported to CMS, 2019-2025
30 companies · $1,308 in 2025
The $1,308 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $235 · 2020: $116 · 2023: $287 · 2024: $907 · 2025: $1,308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,501.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,501.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $443.22 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $391.81 | 2023-2025 | |
| Abbott Laboratories | $282.05 | 2019-2025 | Freestyle Libre 3, Eterna |
| Amgen INC. | $230.26 | 2019-2025 | Tepezza, Repatha, Evenity |
| Radius Health, INC. | $211.05 | 2020-2025 | Tymlos |
| Lilly USA, LLC | $164.71 | 2019-2025 | Zepbound, Jardiance, Mounjaro |
| Beta Bionics, INC. | $98.93 | 2023-2024 | Ilet Bionic Pancreas |
| Bayer Healthcare Pharmaceuticals INC. | $84.42 | 2023-2025 | |
| Insulet Corporation | $83.70 | 2019-2025 | Omnipod |
| Recordati_rare_diseases_inc. | $80.53 | 2025 | Isturisa |
| Abbvie INC. | $75.48 | 2025 | |
| Sanofi-Aventis U.S. LLC | $66.34 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $60.68 | 2019-2020 | |
| Inspire Medical Systems, INC. | $58.14 | 2024-2025 | Inspire |
| Echosens North America, INC. | $50.35 | 2025 | Fibroscan |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cequr Corporation | $49.45 | 2023-2025 | Cequr Simplicity |
| Sequel Med Tech, LLC | $48.58 | 2025 | Twiist |
| Dexcom, INC. | $44.14 | 2019-2025 | Dexcom G6 Transmitter |
| Medtronic Minimed, INC. | $43.22 | 2019 | |
| Tandem Diabetes Care, INC. | $41.13 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.29 | 2024-2025 | Jardiance |
| Medtronic, INC. | $38.34 | 2025 | Minimed 780g |
| Xeris Pharmaceuticals, INC. | $38.17 | 2023-2025 | Gvoke Hypopen |
| Madrigal Pharmaceuticals | $27.07 | 2025 | Rezdiffra |
| Corcept Therapeutics | $24.03 | 2025 | Korlym |
| Antares Pharma, INC. | $21.74 | 2025 | Xyosted |
| Janssen Pharmaceuticals, INC | $15.58 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.05 | 2019 | |
| Amneal Pharmaceuticals LLC | $14.30 | 2025 | Unithroid |
| Merck Sharp & Dohme LLC | $11.16 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rekha Pandula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.